Microbot Medical Introduces the LIBERTY Endovascular Robotic System
Company Completes Essential Preparations for LIBERTY’s U.S. Market Launch; Receives Enthusiastic Support from Medical Professionals
HINGHAM, Mass. – Microbot Medical Inc. (NASDAQ: MBOT) is thrilled to announce that its LIBERTY Endovascular Robotic System is now officially available in a limited market release across the United States. This innovative system, designed for peripheral endovascular procedures, represents a significant advancement in robotic surgery with its unique single-use, remotely operated capabilities.
Key Features and Market Strategy
The LIBERTY system aims to revolutionize how endovascular procedures are conducted, ensuring precision and safety for patients. The initial rollout will focus on specific high-volume regions where there has already been notable interest from healthcare professionals. This strategic approach allows Microbot Medical to gather invaluable real-world feedback and optimize the system's performance ahead of a broader market launch planned for the upcoming Society of Interventional Radiology (SIR) annual meeting in April 2026.
Leadership's Vision and Goals
Harel Gadot, CEO, President, and Chairman of Microbot Medical, expressed his excitement for the LIBERTY system's market entry. “This launch signifies a pivotal moment in our journey,” he stated. “We are on the forefront of developing a new category of robotic systems. Our commitment to innovation, paired with the eagerness we've seen from physicians and hospital officials, lays a strong foundation for fulfilling our goals for this release.”
Steps Taken for Successful Rollout
Since achieving FDA 510(k) clearance for the LIBERTY system, Microbot has made significant strides in preparing for its commercial debut. The company has partnered with a third-party logistics provider and expanded its commercial leadership team. These initiatives are crucial in ensuring a smooth and efficient rollout of the system, reflecting Microbot Medical's commitment to excellence and market responsiveness.
About Microbot Medical
Microbot Medical Inc. is dedicated to transforming the landscape of medical devices, particularly in endovascular procedures. The LIBERTY Endovascular Robotic System encapsulates the firm’s mission to enhance surgical precision while optimizing efficiency and safety. With an extensive intellectual property portfolio backing its innovations, Microbot Medical is poised to lead the way in next-generation medical technologies.
Future Prospects
As the medical landscape continues to evolve, Microbot Medical Inc. remains focused on expanding its product offerings and enhancing patient outcomes. The company is enthusiastic about the potential of its LIBERTY system and is committed to addressing the needs of healthcare providers with cutting-edge technological solutions. The ongoing response from the medical community has further validated the significance of this release.
Frequently Asked Questions
What is the LIBERTY Endovascular Robotic System?
The LIBERTY system is the first FDA cleared single-use, remotely operated robotic system tailored for peripheral endovascular procedures.
How is the Limited Market Release structured?
Microbot Medical will introduce LIBERTY in select regions with high procedure volumes, collecting insights from early adopters to shape its broader rollout.
When will the full market launch occur?
The full market launch is anticipated to coincide with the Society of Interventional Radiology (SIR) annual meeting in April 2026.
Who is Microbot Medical?
Microbot Medical Inc. is a medical device company focused on innovative robotic solutions for endovascular procedures, aimed at enhancing surgical precision and safety.
Where can I find more information about Microbot Medical?
For more information, you can visit Microbot Medical’s website or follow their updates on social media platforms.
